Zafirah Khan
03 9342 7798
Seeking participants for a new Crohn's Disease study
We are evaluating the efficacy and safety of Filgotinib in the induction and maintenance of remission in people with moderately to severely active Crohn’s Disease
Crohn’s disease is an inflammatory disease of the gastrointestinal tract (digestive tract). The purpose of this study is to see if filgotinib, an experimental drug, is effective and safe in treating people with moderate to severe Crohn’s disease.
Anticipated date that enrolment will close: 31 December 2022
Who can take part
- People who have been diagnosed with Crohn's Disease for at least 6 months; and
- People of reproductive potential must be willing to adhere to specified contraceptive methods
What is involved for you
- electro cardiograms (ECGs)
- vital signs will be taken (blood pressure, respiratory rate, heart rate), height , weight
- ileocolonoscopy (with Biopsies)
- urine sample
- stool sample
- blood samples
- questionnaires
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
For more information
Quote reference number
2016.342Nicole Tresize
03 9342 8411